Loading stock…

Eckert & Ziegler SE (EUZ) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Eckert & Ziegler SE

EUZMarket cap $0.85BPrice $13.5

Country🇩🇪Germany

SectorHealthcare

IndustryHealthcare Equipment

Makes radioactive isotopes used in cancer treatment, medical imaging, and radiation therapy devices worldwide. It's one of the few global suppliers keeping hospitals stocked with materials that literally can't be substituted or stockpiled for long.

In Bastion Portfolios?

52W Return-31%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+15%8

Revenue Forecast

Rev CAGR (1y)-2%2

Rev CAGR (3y)+6%5

Rev CAGR (5y)+5%4

Earnings Forecast

EPS Growth Y+1+0%4

EPS Growth Y+2+6%6

EPS Growth Y+3+11%7

Quality

Margins

EBIT Margin24%8

Net Income Margin16%7

Free Cash Flow Margin8%5

Debt

Net Debt/EBITDA-0.810

Efficiency

ROE20%8

ROA11%9

Earnings Stability55

GEAR+AVERAGE62

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)146

P/E Ratio (Forward 3y)126

P/BV2.85

EV Multiples

EV/EBITDA Fwd78

EV/EBIT Fwd99

Yield

Free Cash Flow Yield3.2%5

Dividend Yield1.8%5

Momentum

Short term

1 month return-5%5

3 month return-22%1

YTD return-21%2

Mid term

Price vs 52wHigh68%3

1 year return-31%2

Long term

3 year return+25%4

5 year return-62%1

Risk Shield

Price Risk

Beta1.32

Volatility31%7

Free Cash Flow

Free Cash Flow Margin8%5

Free Cash Flow Yield3.2%5

Quality

ROCE20%9

Earnings Stability55

Net Debt/EBITDA-0.810

02Growth

Is it actually growing, and how fast?

EUZEckert & Ziegler

Revenue FY25$366M

GROWTH RATING↗

AVERAGE39 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+15%8

Revenue, next 1Y-2%2

Revenue, next 3Y, CAGR+6%5

Revenue, next 5Y, CAGR+5%4

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+0%4

EPS growth, FY27E+6%6

EPS growth, FY28E+11%7

GROWTH ASSESSMENT

STRENGTHS

Revenue grew 15%/yr over the last 3 years, ahead of 70% of companies worldwide.8/10

Earnings are set to grow in step with sales (EPS about 6%/yr vs revenue 6%/yr).

WATCH

A mid-pack grower, ahead of 39% of companies worldwide.

Revenue is set to grow 6%/yr over the next 3 years, a little behind the market.4/10

Revenue grew 15%/yr over the last 3 years; forecasts see it cooling to 6%/yr.

Over five years revenue is set to grow 5%/yr, behind 60% of companies worldwide.4/10

WEAKNESSES

None flagged.

BOTTOM LINE

Steady Grower

A middle-of-the-pack grower that is slowing. The one thing to watch: forward revenue growth is only about average.

03Price Momentum

Is the market behind it right now?

EUZEckert & Ziegler

Total return Current528%

Price return Current477%

MOMENTUM RATING↗

VERY WEAK9 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-5%5

3-month return-22%1

YTD return-21%2

MID & LONG-TERM▾SCORE

% of 52-week high68%3

1-year return-31%2

3-year return+25%4

5-year return-62%1

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

Returns sit at the market level over the past month (-5%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (+25% over three years and -62% over five), behind 70% of the market.

It's down 31% over the past year, now 32% below its 52-week high. That is lagging the market.

The stock is underperforming over three months (-22%) and so far this year (-21%).

BOTTOM LINE

Falling Knife

Returns rank poorly over both the short and long run, and the price is still falling. Momentum is firmly negative — catching this is a bet against the tape, not with it. Wait for a base to form. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Eckert & Ziegler SE. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

EUZEckert & Ziegler

Revenue FY25$366M

GROWTH RATING↗

AVERAGE39 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+15%8

Revenue, next 1Y-2%2

Revenue, next 3Y, CAGR+6%5

Revenue, next 5Y, CAGR+5%4

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+0%4

EPS growth, FY27E+6%6

EPS growth, FY28E+11%7

GROWTH ASSESSMENT

STRENGTHS

Revenue grew 15%/yr over the last 3 years, ahead of 70% of companies worldwide.8/10

Earnings are set to grow in step with sales (EPS about 6%/yr vs revenue 6%/yr).

WATCH

A mid-pack grower, ahead of 39% of companies worldwide.

Revenue is set to grow 6%/yr over the next 3 years, a little behind the market.4/10

Revenue grew 15%/yr over the last 3 years; forecasts see it cooling to 6%/yr.

Over five years revenue is set to grow 5%/yr, behind 60% of companies worldwide.4/10

WEAKNESSES

None flagged.

BOTTOM LINE

Steady Grower

A middle-of-the-pack grower that is slowing. The one thing to watch: forward revenue growth is only about average.

03Price Momentum

Is the market behind it right now?

EUZEckert & Ziegler

Total return Current528%

Price return Current477%

MOMENTUM RATING↗

VERY WEAK9 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-5%5

3-month return-22%1

YTD return-21%2

MID & LONG-TERM▾SCORE

% of 52-week high68%3

1-year return-31%2

3-year return+25%4

5-year return-62%1

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

Returns sit at the market level over the past month (-5%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (+25% over three years and -62% over five), behind 70% of the market.

It's down 31% over the past year, now 32% below its 52-week high. That is lagging the market.

The stock is underperforming over three months (-22%) and so far this year (-21%).

BOTTOM LINE

Falling Knife

04Value

Are you paying a fair price for it?

Stop guessing on Eckert & Ziegler SE. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community